Low molecular weight heparin(LMWH) as an anticoagulant during continuous blood purification.
نویسندگان
چکیده
منابع مشابه
Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis.
BACKGROUND The interest of low molecular weight heparins (LMWH) regarding bleeding risk is controversial in renal failure patients. In haemodialysis patients, there are very few data on the pharmacokinetics of LMWH after the end of the session. The aim of the study was to evaluate the duration of anticoagulation after bolus administration of the LMWH enoxaparin at the start of haemodialysis. ...
متن کاملHomogeneous low-molecular-weight heparins with reversible anticoagulant activity.
Low-molecular-weight heparins (LMWHs) are carbohydrate-based anticoagulants clinically used to treat thrombotic disorders, but impurities, structural heterogeneity or functional irreversibility can limit treatment options. We report a series of synthetic LMWHs prepared by cost-effective chemoenzymatic methods. The high activity of one defined synthetic LMWH against human factor Xa (FXa) was rev...
متن کاملLow-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement.
BACKGROUND After mechanical heart valve replacement (MHVR), long-term use of unfractionated heparin is sometimes required because vitamin K antagonists (VKA) are temporarily contraindicated or because the time to reach the target international normalized ratio is long. The aim of this study was to investigate the feasibility of low-molecular-weight heparin treatment in these patients. METHODS...
متن کاملSafety and cost of low-molecular-weight heparin as bridging anticoagulant therapy in subacute cerebral ischemia.
BACKGROUND AND PURPOSE Anticoagulation with intravenous unfractionated heparin (IVUH) while awaiting therapeutic oral anticoagulant levels is a common practice in patients with acute and subacute cerebral ischemia. A promising alternative strategy is to use bridging subcutaneous low-molecular-weight heparin (LMWH), which may have a favorable risk-benefit profile compared with IVUH and may permi...
متن کاملExclusive low-molecular-weight heparin as bridging anticoagulant after mechanical valve replacement.
BACKGROUND Unfractionated heparin has been the standard anticoagulant used immediately after mechanical heart valve replacement (MHVR). The purpose of this study was to assess a postoperative anticoagulation protocol with low-molecular-weight heparin (LMWH) immediately after MHVR without the use of unfractionated heparin or anti-factor Xa monitoring. METHODS We performed a prospective, single...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Japanese Society for Dialysis Therapy
سال: 1992
ISSN: 0911-5889,1884-6211
DOI: 10.4009/jsdt1985.25.1147